Markets Nosedive
Sensex loses 388 points, Nifty ends below 6,000 on Fed, China concerns
The Nifty posted its biggest percentage fall in a year on Thursday, as the prospect of an end to the U.S. stimulus programme and a weak China manufacturing survey sparked concerns foreign investors would end their recent buying spree. Full Article
Reuters Showcase
Sino-Pakistan Relations
China's Li effusive in praise of Pakistan, but not everyone buys it. Full Article | Related Story
International Booker
Short story writer Lydia Davis wins Man Booker International fiction prize. Full Article
Reuters India Mobile
Get the latest news on the go. Visit Reuters India on your mobile device. Full Coverage
Aurobindo uses patent pool for generic AIDS drugs
LONDON |
LONDON (Reuters) - Aurobindo Pharma has become the first major generic drugmaker to join a patent pool designed to make HIV/AIDS treatments more widely available to the poor, paving the way for it to sell cheap medicines in many countries.
The Medicines Patent Pool said on Tuesday the agreement would allow Aurobindo to make a range of AIDS drugs licensed to the pool by Gilead Sciences, the leading maker of HIV drugs, in July.
Aurobindo has also elected to take advantage of a key provision in the pool's licences in order to sell one drug, tenofovir, to a wide range of countries without paying royalties. These could include several middle-income countries such as Argentina, Brazil, Chile, Colombia, Malaysia, the Philippines, Ukraine and Uruguay.
Around 33 million people worldwide have the human immunodeficiency virus (HIV) that causes AIDS. Most live in Africa and Asia, where medicines have to be very cheap to allow those who need them to be able to afford them.
The Medicines Patent Pool, launched by the UNITAID health financing system that is funded by a tax on airline tickets, aims to address the problem by creating a system for patent holders to license technology to makers of cheap generics.
(Reporting by Ben Hirschler; Editing by David Holmes)
- Tweet this
- Link this
- Share this
- Digg this
- Reprints





Follow Reuters